Harpreet Singh, Immatics CEO
Immatics announces multiple pipeline changes with latest financial results
The T-cell biotech Immatics is looking to make some changes to its pipeline.
Immatics released its 2022 financial results on Tuesday and announced that it’s planning to discontinue its program for IMA201, an experimental cell therapy for solid tumors that express the antigens known as MAGE4/8. It plans to shift focus to IMA401, a TCR bispecific which goes after the same target. IMA401 also has better potency and was developed more recently according to Immatics CEO Harpreet Singh, in an interview with Endpoints News.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters